{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:20:03Z","timestamp":1773998403356,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,31]],"date-time":"2015-03-31T00:00:00Z","timestamp":1427760000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12883-015-0300-x","type":"journal-article","created":{"date-parts":[[2015,3,31]],"date-time":"2015-03-31T00:38:16Z","timestamp":1427762296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases"],"prefix":"10.1186","volume":"15","author":[{"given":"Zdenek","family":"Rohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Smetakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaromir","family":"Kukal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Rusina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radoslav","family":"Matej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,31]]},"reference":[{"issue":"3","key":"300_CR1","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.pharmthera.2011.01.003","volume":"130","author":"MN Adams","year":"2011","unstructured":"Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, et al. Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther. 2011;130(3):248\u201382.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"300_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.brainresrev.2007.08.002","volume":"56","author":"W Luo","year":"2007","unstructured":"Luo W, Wang Y, Reiser G. Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev. 2007;56(2):331\u201345.","journal-title":"Brain Res Rev"},{"issue":"Pt 9","key":"300_CR3","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1099\/vir.0.043877-0","volume":"93","author":"R Matej","year":"2012","unstructured":"Matej R, Olejar T, Janouskova O, Holada K. Deletion of protease-activated receptor 2 prolongs survival of scrapie-inoculated mice. J Gen Virol. 2012;93(Pt 9):2057\u201361.","journal-title":"J Gen Virol"},{"issue":"3","key":"300_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2013.10","volume":"9","author":"L Parnetti","year":"2013","unstructured":"Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol. 2013;9(3):131\u201340.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"300_CR5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JAD-130995","volume":"38","author":"L Kaerst","year":"2014","unstructured":"Kaerst L, Kuhlmann A, Wedekind D, Stoeck K, Lange P, Zerr I. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson\u2019s disease, and Alzheimer\u2019s disease. J Alzheimers Dis. 2014;38(1):63\u201373.","journal-title":"J Alzheimers Dis"},{"key":"300_CR6","doi-asserted-by":"crossref","unstructured":"Hu WT, Watts K, Grossman M, Glass J, Lah JJ, Hales C, et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology. 2013;81(22):1945-52","DOI":"10.1212\/01.wnl.0000436625.63650.27"},{"issue":"5","key":"300_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.5414\/NPP29271","volume":"29","author":"GG Kovacs","year":"2010","unstructured":"Kovacs GG, Budka H. Current concepts of neuropathological diagnostics in practice: neurodegenerative diseases. Clin Neuropathol. 2010;29(5):271\u201388.","journal-title":"Clin Neuropathol"},{"key":"300_CR8","doi-asserted-by":"crossref","unstructured":"Muayqil T, Gronseth G, Camicioli R. Evidence-based guideline: diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(14):1499\u2013506","DOI":"10.1212\/WNL.0b013e31826d5fc3"},{"issue":"Pt 10","key":"300_CR9","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1093\/brain\/aws238","volume":"135","author":"K Stoeck","year":"2012","unstructured":"Stoeck K, Sanchez-Juan P, Gawinecka J, Green A, Ladogana A, Pocchiari M, et al. Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10\u00a0years. Brain. 2012;135(Pt 10):3051\u201361.","journal-title":"Brain"},{"issue":"1","key":"300_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1212\/WNL.0b013e31823ed0f0","volume":"78","author":"NS Schoonenboom","year":"2012","unstructured":"Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012;78(1):47\u201354.","journal-title":"Neurology"},{"issue":"2","key":"300_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00415-010-5738-6","volume":"258","author":"Z Meiner","year":"2011","unstructured":"Meiner Z, Kahana E, Baitcher F, Korczyn A, Chapman J, Cohen O, et al. Tau and 14-3-3 of genetic and sporadic Creutzfeldt\u2013Jakob disease patients in Israel. J Neurol. 2011;258(2):255\u201362.","journal-title":"J Neurol"},{"issue":"10","key":"300_CR12","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s00415-009-5163-x","volume":"256","author":"A Ladogana","year":"2009","unstructured":"Ladogana A, Sanchez-Juan P, Mitrova E, Green A, Cuadrado-Corrales N, Sanchez-Valle R, et al. Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. J Neurol. 2009;256(10):1620\u20138.","journal-title":"J Neurol"},{"issue":"4","key":"300_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1212\/01.wnl.0000230159.67128.00","volume":"67","author":"P Sanchez-Juan","year":"2006","unstructured":"Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Saanchez-Valle R, Mitrovaa E, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology. 2006;67(4):637\u201343.","journal-title":"Neurology"},{"issue":"3","key":"300_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131\u201344.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"300_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/mds.24002","volume":"27","author":"R Matej","year":"2012","unstructured":"Matej R, Kovacs GG, Johanidesova S, Keller J, Matejckova M, Novakova J, et al. Genetic Creutzfeldt-Jakob disease with R208H mutation presenting as progressive supranuclear palsy. Mov Disord. 2012;27(4):476\u20139.","journal-title":"Mov Disord"},{"issue":"1","key":"300_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1468-1331.2009.02753.x","volume":"17","author":"J Hort","year":"2010","unstructured":"Hort J, Bartos A, Pirttila T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol. 2010;17(1):90\u20136.","journal-title":"Eur J Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-015-0300-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0300-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0300-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-015-0300-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T10:12:54Z","timestamp":1630577574000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-015-0300-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,31]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["300"],"URL":"https:\/\/doi.org\/10.1186\/s12883-015-0300-x","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,31]]},"assertion":[{"value":"14 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"50"}}